Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.

Rajshekhar ChakrabortyIrbaz Bin RiazSaad Ullah MalikNaimisha MarneniAlex Mejia GarciaFaiz AnwerAlok A KhoranaS Vincent RajkumarShaji K KumarM Hassan MuradZhen WangSafi U KhanNavneet S Majhail

Published in: Cancer (2020)

Despite adequate thromboprophylaxis, lenalidomide-based regimens have a substantial risk of VTE in controlled clinical trial settings. Further studies are needed on new thromboprophylaxis strategies with regimens that have a high VTE risk.

Keyphrases

venous thromboembolism
multiple myeloma
direct oral anticoagulants
clinical trial
newly diagnosed
stem cell transplantation
double blind